Aquestive Therapeutics is trading 17.89% higher at $4.48 in pre-market, with no new company-specific announcement found explaining the November 5 move. - The November 3 earnings release and November 4 call reported third-quarter revenue of $7.6 million, down from $12.8 million a year earlier; the company reiterated its 2026 outlook and highlighted Anaphylm’s March 16, 2027 FDA decision date. - Biotech rose 2.08% in pre-market, but evidence does not establish it as the cause; earnings and the regulatory timeline do not clearly explain the gain.